Advertisement
New Zealand markets closed

  • NZX 50

    12,447.68
    +94.07 (+0.76%)
     

  • NZD/USD

    0.6252
    -0.0008 (-0.13%)
     

  • NZD/EUR

    0.5652
    +0.0006 (+0.11%)
     

  • ALL ORDS

    8,316.70
    +53.10 (+0.64%)
     

  • ASX 200

    8,091.90
    +46.80 (+0.58%)
     

  • OIL

    73.65
    -2.26 (-2.98%)
     

  • GOLD

    2,536.00
    -24.30 (-0.95%)
     

  • NASDAQ

    19,574.64
    +249.18 (+1.29%)
     

  • FTSE

    8,376.63
    -3.01 (-0.04%)
     

  • Dow Jones

    41,563.08
    +228.03 (+0.55%)
     

  • DAX

    18,906.92
    -5.65 (-0.03%)
     

  • Hang Seng

    17,989.07
    +202.75 (+1.14%)
     

  • NIKKEI 225

    38,647.75
    +285.22 (+0.74%)
     

  • NZD/JPY

    91.3530
    +0.6310 (+0.70%)
     

Why AbbVie and Amgen Are Moving Lower Today

George Budwell, The Motley Fool
·2-min read
Why AbbVie and Amgen Are Moving Lower Today

Shares of the immunology juggernaut AbbVie (NYSE: ABBV) were down by 4% on sky-high volume as of 11 a.m. ET Thursday. The big loss came after Coherus Biosciences announced a partnership with billionaire Mark Cuban's pharmaceuticals start-up -- known as the Mark Cuban Cost Plus Drug Company -- to sell a biosimilar (a generic biologic) version of AbbVie's flagship anti-inflammatory medication, Humira, at an 85% discount. Coherus' biosimilar will be branded as Yusimry.

Continue reading